Societe Generale downgraded Eli Lilly to Sell from Hold with a price target of $278, up from $202. Eli Lilly’s FY23 guidance "did not surprise" and new product launches should drive growth above the sector average, but the firm says its "time to take profits" with shares and valuation compared to peers close to an all-time high.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
- Eli Lilly’s (NYSE:LLY) Growth Slowdown Doesn’t Take Away from Its Bull Case
- Eli Lilly to supply API for insulin at reduced price to IABL
- Eli Lilly price target raised to $455 from $440 at Morgan Stanley
- Eli Lilly’s net price for Mounjaro did not decline in Q4, says Evercore ISI
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
